Form 4: Ventyx Biosciences Executive John Nuss Reports Stock Unit Vesting
SEC Form 4
Chief Scientific Officer John Nuss of Ventyx Biosciences reports the vesting of restricted stock units, resulting in the acquisition of 4,531 shares of common stock.
Summary
- On March 28, 2024, John Nuss, the Chief Scientific Officer of Ventyx Biosciences, reported the vesting of 4,531 restricted stock units (RSUs).
- These RSUs converted into 4,531 shares of Ventyx Biosciences common stock.
- Following this transaction, Nuss directly owns 266,649 shares of Ventyx Biosciences common stock and 13,594 restricted stock units.
- The RSUs vest over four years, with 25% vesting annually starting from March 28, 2023, contingent upon continued service.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting scheduled vesting of stock units as part of executive compensation.
Future Outlook
The remaining restricted stock units will continue to vest in the future, contingent upon the reporting person's continued service with the company.
Industry Context
This is a routine disclosure related to executive compensation and is common for publicly traded companies. It provides transparency into the equity holdings of company insiders.
Stakeholder Impact
- The vesting of RSUs may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/28/2023 | RSU Vesting Commencement Date |
| 03/28/2024 | Date of transaction (RSU vesting) |
| 03/29/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.